Abstract
Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Current Cancer Therapy Reviews
Title: The Role of FDA in the Regulation of Anti-Cancer Drugs
Volume: 2 Issue: 4
Author(s): Ramzi N. Dagher and Richard Pazdur
Affiliation:
Keywords: investigational drug application (IND), post-marketing, new drug application (NDA), Clinical trials, Drug development
Abstract: Oncology drug development is an increasingly complex effort involving multiple stakeholders on a global scale. This review summarizes the role of the United States Food and Drug Administration (USFDA) and its office of oncology drugs in the regulation of anticancer drug therapies. The regulatory history of FDAs mission will be summarized. The FDAs role from first-in-human dose finding studies to trials designed to evaluate efficacy, as well as post-marketing considerations will be outlined. During this entire process, the FDA is committed to productive interactions with all its stakeholders, including the public, the pharmaceutical industry, academia, other government agencies and patient advocacy groups.
Export Options
About this article
Cite this article as:
Dagher N. Ramzi and Pazdur Richard, The Role of FDA in the Regulation of Anti-Cancer Drugs, Current Cancer Therapy Reviews 2006; 2 (4) . https://dx.doi.org/10.2174/157339406778699196
DOI https://dx.doi.org/10.2174/157339406778699196 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hepatitis B Virus (HBV) Infection and Hepatocellular Carcinoma- New Insights for an Old Topic
Current Cancer Drug Targets Antiangiogenic Therapy in Acute Myelogenous Leukemia: Targeting of Vascular Endothelial Growth Factor and Interleukin 8 as Possible Antileukemic Strategies
Current Cancer Drug Targets Lymphatic Targeting of Nanosystems for Anticancer Drug Therapy
Current Pharmaceutical Design Editorial (Thematic Issue: Emergence of the “New” Head and Neck Cancer Prevailing to Young, Nonsmoker, and Nondrinker - Oropharyngeal Cancer Associated with HPV Positive)
Current Cancer Therapy Reviews Identifying Changes in the Synaptic Proteome of Cirrhotic Alcoholic Superior Frontal Gyrus
Current Neuropharmacology Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
Current Cancer Drug Targets Exploring Genetic Influences on Cognition: Emerging Strategies for Target Validation and Treatment Optimization
Current Drug Targets - CNS & Neurological Disorders Activation of Large Form Galanin-LI by Extracellular Processing in Small Cell Lung Carcinoma Tissue
Protein & Peptide Letters Patent Selections
Recent Patents on Anti-Cancer Drug Discovery SENP1 as A Biomarker for the Diagnosis of Cancer: Review of the Science and Published Patents
Recent Patents on Biomarkers Lung Cancer Epidemiology - A Global View
Current Respiratory Medicine Reviews 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience
Current Radiopharmaceuticals GRAPHICAL ABSTRACTS
Letters in Drug Design & Discovery Molecular Mechanisms of Liver Cancer
Anti-Cancer Agents in Medicinal Chemistry Vertebrae Segmentation in 3D CT Data: A Review of Methods and Evaluation Approaches
Current Medical Imaging Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design